Skip to main content
ARTV
NASDAQ Life Sciences

RA Capital Makes Massive $100M Purchase in Artiva Biotherapeutics

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Positive
Importance info
9
Price
$10.29
Mkt Cap
$259.525M
52W Low
$1.47
52W High
$14.53
52W Position info
600% above low
Off High info
29% below high
Rel. Volume info
1.3× avg
Market data snapshot near publication time

ARTV has more than doubled off its 52-week low of $1.47.

Summary

RA Capital, a major institutional investor and director, made a substantial $100 million purchase of Artiva Biotherapeutics stock and warrants at the offering price of $11.52, signaling strong confidence following the company's recent $300 million public offering.


Key Events · Ownership and Investor Activity · ARTV

  • Significant Insider Purchase

    RA Capital, a 10% owner and director, acquired $99,999,765 worth of common stock and pre-funded warrants on May 11, 2026.

  • Participation in Public Offering

    This purchase was made at the offering price of $11.52 per share/warrant, following the company's $300 million public offering on May 8, 2026.

  • Strong Vote of Confidence

    The substantial investment, representing 38.5% of the company's market capitalization, signals strong conviction from a major institutional investor and board member.

  • Premium to Current Market

    The purchase price of $11.52 is above the current stock price of $10.29, indicating confidence in the company's valuation.


Analysis · ARTV · Life Sciences

This Form 4 reveals a massive vote of confidence from RA Capital, a significant institutional investor and board member, who purchased nearly $100 million in Artiva Biotherapeutics shares and pre-funded warrants. This transaction, occurring just days after the company's $300 million public offering, demonstrates RA Capital's strong conviction in the company's future, especially as the purchase price of $11.52 per share/warrant is above the current market price. Such a substantial investment, representing 38.5% of the company's market cap, significantly bolsters the company's capital position and investor sentiment following the recent capital raise.

How filings like this one have moved

In the 30 days to Nov 17, 2026, 52.4% of the 208 measured filings Wiseek scored 9 moved their stock by 5% or more by the next session's close. The median move was -1.91%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARTV was trading at $10.29 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $259.5M. The 52-week trading range was $1.47 to $14.53. This filing was assessed with positive market sentiment and an importance score of 9 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARTV - Latest Insights

ARTV
Nov 09, 2026, 4:04 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $4.22
Real-time Price: $3.82 info
Change: -$0.400 (-9%) info
Market Cap: $186.854M info
ARTV
Oct 27, 2026, 8:30 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $4.09
Real-time Price: $3.82 info
Change: -$0.270 (-7%) info
Market Cap: $186.854M info
ARTV
Oct 27, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
10
Price at Filing: $6.30
Real-time Price: $3.82 info
Change: -$2.48 (-39%) info
Market Cap: $186.854M info
ARTV
Oct 01, 2026, 7:30 AM EDT
Source: Wiseek News
Importance Score:
7
Price at Filing: $7.25
Real-time Price: $3.82 info
Change: -$3.43 (-47%) info
Market Cap: $186.854M info
ARTV
Aug 06, 2026, 4:09 PM EDT
Filing Type: 8-K
Importance Score:
8
Price at Filing: $11.58
Real-time Price: $3.82 info
Change: -$7.76 (-67%) info
Market Cap: $186.854M info